Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02502266
Recruitment Status : Recruiting
First Posted : July 20, 2015
Last Update Posted : November 21, 2019
Sponsor:
Collaborator:
NRG Oncology
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned (recurrent) after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.

Condition or disease Intervention/treatment Phase
Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Fallopian Tube Undifferentiated Carcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Carcinoma Ovarian Undifferentiated Carcinoma Primary Peritoneal Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Drug: Cediranib Drug: Cediranib Maleate Drug: Olaparib Drug: Paclitaxel Drug: Pegylated Liposomal Doxorubicin Hydrochloride Other: Questionnaire Administration Drug: Topotecan Drug: Topotecan Hydrochloride Phase 2 Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 680 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Actual Study Start Date : February 5, 2016
Estimated Primary Completion Date : June 30, 2023


Arm Intervention/treatment
Active Comparator: Phase II Arm I (reference regimen)
Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel IV on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. (12/05/2016)
Drug: Paclitaxel
Given IV
Other Names:
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol
  • Taxol Konzentrat

Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Given IV
Other Names:
  • ATI-0918
  • Caelyx
  • DOX-SL
  • Doxil
  • Doxilen
  • Doxorubicin HCl Liposomal
  • Doxorubicin HCl Liposome
  • doxorubicin hydrochloride liposome
  • Duomeisu
  • Evacet
  • LipoDox
  • Lipodox 50
  • Liposomal Adriamycin
  • Liposomal Doxorubicin Hydrochloride
  • Liposomal-Encapsulated Doxorubicin
  • Pegylated Doxorubicin HCl Liposome
  • S-Liposomal Doxorubicin
  • Stealth Liposomal Doxorubicin
  • TLC D-99

Other: Questionnaire Administration
Ancillary studies

Drug: Topotecan
Given IV
Other Names:
  • Hycamptamine
  • Topotecan Lactone

Drug: Topotecan Hydrochloride
Given IV
Other Names:
  • Hycamptamine
  • Hycamtin
  • SKF S-104864-A
  • Topotecan HCl
  • topotecan hydrochloride (oral)

Experimental: Phase II Arm II (cediranib maleate, olaparib)
Patients receive cediranib maleate PO QD and olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Cediranib
Given PO
Other Name: AZD2171

Drug: Cediranib Maleate
Given PO
Other Names:
  • AZD2171
  • AZD2171 Maleate
  • Recentin

Drug: Olaparib
Given PO
Other Names:
  • AZD 2281
  • AZD-2281
  • AZD2281
  • KU-0059436
  • Lynparza
  • PARP inhibitor AZD2281

Other: Questionnaire Administration
Ancillary studies

Experimental: Phase II Arm III (cediranib maleate)
Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Cediranib
Given PO
Other Name: AZD2171

Drug: Cediranib Maleate
Given PO
Other Names:
  • AZD2171
  • AZD2171 Maleate
  • Recentin

Other: Questionnaire Administration
Ancillary studies

Experimental: Phase II Arm IV (olaparib)
Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).
Drug: Olaparib
Given PO
Other Names:
  • AZD 2281
  • AZD-2281
  • AZD2281
  • KU-0059436
  • Lynparza
  • PARP inhibitor AZD2281

Other: Questionnaire Administration
Ancillary studies

Active Comparator: Phase III Arm I (reference regimen)
Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. (12/05/2016)
Drug: Paclitaxel
Given IV
Other Names:
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol
  • Taxol Konzentrat

Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Given IV
Other Names:
  • ATI-0918
  • Caelyx
  • DOX-SL
  • Doxil
  • Doxilen
  • Doxorubicin HCl Liposomal
  • Doxorubicin HCl Liposome
  • doxorubicin hydrochloride liposome
  • Duomeisu
  • Evacet
  • LipoDox
  • Lipodox 50
  • Liposomal Adriamycin
  • Liposomal Doxorubicin Hydrochloride
  • Liposomal-Encapsulated Doxorubicin
  • Pegylated Doxorubicin HCl Liposome
  • S-Liposomal Doxorubicin
  • Stealth Liposomal Doxorubicin
  • TLC D-99

Other: Questionnaire Administration
Ancillary studies

Drug: Topotecan
Given IV
Other Names:
  • Hycamptamine
  • Topotecan Lactone

Drug: Topotecan Hydrochloride
Given IV
Other Names:
  • Hycamptamine
  • Hycamtin
  • SKF S-104864-A
  • Topotecan HCl
  • topotecan hydrochloride (oral)

Experimental: Phase III Arm II (cediranib maleate, olaparib)
Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II.
Drug: Cediranib
Given PO
Other Name: AZD2171

Drug: Cediranib Maleate
Given PO
Other Names:
  • AZD2171
  • AZD2171 Maleate
  • Recentin

Drug: Olaparib
Given PO
Other Names:
  • AZD 2281
  • AZD-2281
  • AZD2281
  • KU-0059436
  • Lynparza
  • PARP inhibitor AZD2281

Other: Questionnaire Administration
Ancillary studies

Experimental: Phase III Arm III (single-agent cediranib maleate)
Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Cediranib
Given PO
Other Name: AZD2171

Drug: Cediranib Maleate
Given PO
Other Names:
  • AZD2171
  • AZD2171 Maleate
  • Recentin

Other: Questionnaire Administration
Ancillary studies




Primary Outcome Measures :
  1. Progression-free survival (PFS) (Phase II and Phase III) [ Time Frame: Time from study enrollment to the onset of progression as determined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST) criteria, or death due to any cause, whichever occurs first, assessed up to 5 years ]
    Progression-free survival will be assessed. The primary analysis of PFS proportional hazards model with patients analyzed according to the arm to which they were randomized, regardless of whether treatment is received.

  2. Overall survival (OS) (Phase III) [ Time Frame: Time from study enrollment to death due to any cause, assessed up to 5 years ]
    Overall survival will be evaluated. To allow for better understanding of time to subsequent therapy and OS, patients on experimental study drug(s) or standard chemotherapy arm will be followed after progression, with data capture to include the date of initiation of the subsequent therapy, detailed information on the type of subsequent therapy received, and time to progression on the subsequent therapy.


Secondary Outcome Measures :
  1. Objective response rate (partial or complete response) (Phase II and Phase III) [ Time Frame: Up to 5 years ]
    Objective response rate will be defined by RECIST 1.1.

  2. Incidence of adverse events (Phase II and Phase III) [ Time Frame: Up to 5 years ]
    Frequency and severity of adverse events measured by Common Terminology Criteria for Adverse Events version 4.0


Other Outcome Measures:
  1. Patient-reported scores of disease-related symptoms [ Time Frame: Up to 5 years ]
    Measured by the 9-item Disease Related Symptoms (DRS-9) subscale of the National Comprehensive Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) Ovarian Symptom Index (NFOSI-18).

  2. Gene mutations assessed BROCA-HR [ Time Frame: Up to 5 years ]
    A single proportional hazards model will be used to estimate the treatment hazard ratios (and variances) for each of the experimental treatments selected for phase III evaluation relative to the reference treatment (chemotherapy) group. The model will include adjustments for prior platinum-free interval, prior bevacizumab treatment, age at study enrollment, randomly assigned study treatment and BROCA-HR status. The estimated hazard ratio(s) for BROCA-HR and the corresponding confidence intervals will be depicted with a forest plot, and assessed for qualitative interaction(s).

  3. Change in circulating endothelial cell levels [ Time Frame: Baseline up to 5 years ]
    A proportional hazards model will be used to assess a linear association between the change in circulating endothelial cell values and the log relative hazard of death within each treatment group. Sensitivity analyses will include known prognostic factors in the model. A plot of the martingale residuals or estimated relative hazards by change in circulating endothelial cell quintiles will be used to qualitatively assess the assumption of a linear relationship between the change in circulating endothelial cell values and the log relative hazard.

  4. Biomarkers in plasma angiome [ Time Frame: Up to 5 years ]
    A proportional hazards model will be used to assess whether the pretreatment values of any of these analytes have a prognostic association with overall survival. The model will include clinical covariates: age, performance status, and the randomly assigned study treatment. Proportional hazards models will be used to assess the relationship between patients' analyte values and log hazard. A proportional hazards model will be used to assess the potential predictive associations between analytes, treatment and survival.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of either serous or endometrioid cancer based on local histopathological findings; both endometrioid and serous histology should be high-grade for eligibility of non-mutation carriers; patients with clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory

    • Note: Due to the long acceptance of BRCA testing through Myriad, Myriad testing will be accepted; if testing for BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germ line deleterious BRCA 1 or BRCA 2 mutation or BRCA rearrangement is required; a copy of Myriad or other BRCA mutational analysis (positive or variants of unknown significance [VUS] or negative) reports will be requested but not required for study enrollment
  • Patients should have recurrent platinum-resistant or- refractory disease - defined as disease that has progressed by imaging while receiving platinum or had recurrence within 6 months of the last receipt of platinum-based chemotherapy; rising CA125 only is not considered as platinum-resistant or refractory disease
  • Phase II study: measurable disease by RECIST 1.1 criteria; if archival tumor sample is not available tumor sample from fresh biopsy is acceptable
  • Phase III study: evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a cancer antigen [CA]125 >= 2 x upper limit of normal [ULN])
  • No more than 3 prior treatment regimens (including primary therapy; no more than 1 prior non-platinum based therapy in the platinum-resistant/-refractory setting); hormonal therapies used as single agents (i.e. tamoxifen, aromatase inhibitors) will not count towards this line limit
  • Patients may not have had a prior anti-angiogenic agent in the recurrent setting; prior use of bevacizumab in the upfront or upfront maintenance setting is allowed
  • Patients may not have previously received a PARP-inhibitor
  • Patient must have provided study specific informed consent prior to study entry
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Hemoglobin >= 10 g/dL
  • Total bilirubin within =< 1.5 times the upper limit of normal (ULN) institutional limits
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN; if intrahepatic liver metastases are present, AST and ALT must be =< 5 times institutional ULN
  • Creatinine =< 1.5 x the institutional ULN
  • Urine protein: creatinine ratio urine protein creatinine (UPC) of =< 1 OR less than or equal to 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart; UPC is the preferred test; patients with 2+ proteinuria on dipstick must also have a 24-hour urine collection demonstrating protein of =< 500 mg over 24 hours
  • Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE; patients with long-standing stable grade 2 neuropathy may be considered after discussion with the study chair.
  • Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on maximum of three antihypertensive medications; patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; it is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on protocol; patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to cediranib alone and the combination of olaparib and cediranib arms
  • Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid-stimulating hormone (TSH) within normal limits
  • Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib
  • Cediranib has been shown to terminate fetal development in the rat, as expected for a process dependent on VEGF signaling; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 weeks after cediranib discontinuation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • Olaparib adversely affects embryofetal survival and development in the rat; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 3 months after the last dose of olaparib; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions
  • Any other investigational agents within the past 4 weeks
  • Prior treatment affecting the VEGF/VEGFR pathway or the angiopoietin pathway in the recurrent setting, including but not limited to thalidomide, bevacizumab, sunitinib, sorafenib, pazopanib, cediranib, nintedanib, and trebananib; bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowed
  • Prior use of PARP-inhibitors
  • CA-125 only disease without Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable or otherwise evaluable disease
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
  • Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugs
  • History of intra-abdominal abscess within the past 3 months
  • History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least 6 months, and patient is deemed to be at low risk of recurrent fistula
  • Dependency on IV hydration or total parenteral nutrition (TPN)
  • Any concomitant or prior invasive malignancies with the following curatively treated exceptions:

    • Treated limited stage basal cell or squamous cell carcinoma of the skin
    • Carcinoma in situ of the breast or cervix
    • Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade 1 or 2, no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions
    • Prior cancer treated with a curative intent with no evidence of recurrent disease 5 years following diagnosis and judged by the investigator to be at low risk of recurrence
  • Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events; patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study drug
  • Patients with any of the following:

    • History of myocardial infarction within six months
    • Unstable angina
    • Resting electrocardiogram (ECG) with clinically significant abnormal findings
    • New York Heart Association functional classification of III or IV
  • If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines

    • Patients with the following risk factors should have a baseline cardiac function assessment:

      • Prior treatment with anthracyclines
      • Prior treatment with trastuzumab
      • Prior central thoracic radiation therapy (RT), including RT to the heart
      • History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)
      • Prior history of impaired cardiac function
  • History of stroke or transient ischemic attack within six months
  • Clinical significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)
  • Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
  • Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated

    • No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)
  • Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements
  • Known human immunodeficiency virus (HIV)-positive individuals are ineligible because of the potential for pharmacokinetic interactions with cediranib or olaparib; in addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy
  • Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible

    • Strong inhibitors and inducers of UGT/PgP should be used with caution
  • Pregnant women are excluded from this study because cediranib and olaparib are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with cediranib and olaparib, breastfeeding should be discontinued if the mother is treated with cediranib or olaparib; these potential risks may also apply to other agents used in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02502266


  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham Cancer Center Recruiting
Birmingham, Alabama, United States, 35233
Contact: Site Public Contact    205-934-0220    tmyrick@uab.edu   
Principal Investigator: Charles A. Leath         
United States, Alaska
Alaska Women's Cancer Care Recruiting
Anchorage, Alaska, United States, 99508
Contact: Site Public Contact    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Dan S. Zuckerman         
Providence Alaska Medical Center Suspended
Anchorage, Alaska, United States, 99508
United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Site Public Contact    501-686-8274      
Principal Investigator: Kristin K. Zorn         
United States, California
Sutter Auburn Faith Hospital Recruiting
Auburn, California, United States, 95602
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Deepti Behl         
Mercy San Juan Medical Center Suspended
Carmichael, California, United States, 95608
Marin Cancer Care Inc Recruiting
Greenbrae, California, United States, 94904
Contact: Site Public Contact    415-925-5000    info@marinspecialtycare.com   
Principal Investigator: Peter D. Eisenberg         
UC San Diego Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Contact: Site Public Contact    858-822-5354    cancercto@ucsd.edu   
Principal Investigator: Michael T. McHale         
Palo Alto Medical Foundation-Camino Division Recruiting
Mountain View, California, United States, 94040
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Deepti Behl         
Palo Alto Medical Foundation-Gynecologic Oncology Recruiting
Mountain View, California, United States, 94040
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Deepti Behl         
Kaiser Permanente-Oakland Recruiting
Oakland, California, United States, 94611
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Ramey D. Littell         
Palo Alto Medical Foundation Health Care Suspended
Palo Alto, California, United States, 94301
Sutter Roseville Medical Center Recruiting
Roseville, California, United States, 95661
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Deepti Behl         
Kaiser Permanente Downtown Commons Recruiting
Sacramento, California, United States, 95814
Contact: Site Public Contact    877-642-4691    kpoct@kp.org   
Principal Investigator: Ramey D. Littell         
Mercy Cancer Center - Sacramento Recruiting
Sacramento, California, United States, 95816
Contact: Site Public Contact    916-556-3301    OncologyResearch@DignityHealth.org   
Principal Investigator: Delphine W. Ong         
Sutter Medical Center Sacramento Recruiting
Sacramento, California, United States, 95816
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Deepti Behl         
University of California Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Site Public Contact    916-734-3089      
Principal Investigator: Vanessa A. Kennedy         
Kaiser Permanente - Sacramento Suspended
Sacramento, California, United States, 95825
California Pacific Medical Center-Pacific Campus Recruiting
San Francisco, California, United States, 94115
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Deepti Behl         
Kaiser Permanente-San Francisco Recruiting
San Francisco, California, United States, 94115
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Ramey D. Littell         
UCSF Medical Center-Mission Bay Suspended
San Francisco, California, United States, 94158
Pacific Central Coast Health Center-San Luis Obispo Active, not recruiting
San Luis Obispo, California, United States, 93401
Kaiser Permanente Medical Center - Santa Clara Recruiting
Santa Clara, California, United States, 95051
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Ramey D. Littell         
Palo Alto Medical Foundation-Santa Cruz Suspended
Santa Cruz, California, United States, 95065
Sutter Pacific Medical Foundation Suspended
Santa Rosa, California, United States, 95403
Palo Alto Medical Foundation-Sunnyvale Recruiting
Sunnyvale, California, United States, 94086
Contact: Site Public Contact    415-209-2686    bernicl@sutterhealth.org   
Principal Investigator: Deepti Behl         
Kaiser Permanente-Vallejo Recruiting
Vallejo, California, United States, 94589
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Ramey D. Littell         
Kaiser Permanente-Walnut Creek Recruiting
Walnut Creek, California, United States, 94596
Contact: Site Public Contact    877-642-4691    Kpoct@kp.org   
Principal Investigator: Ramey D. Littell         
Woodland Memorial Hospital Recruiting
Woodland, California, United States, 95695
Contact: Site Public Contact    916-556-3301    OncologyResearch@DignityHealth.org   
Principal Investigator: Delphine W. Ong         
United States, Colorado
University of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Site Public Contact    720-848-0650      
Principal Investigator: Kian Behbakht         
Penrose-Saint Francis Healthcare Suspended
Colorado Springs, Colorado, United States, 80907
UCHealth Memorial Hospital Central Recruiting
Colorado Springs, Colorado, United States, 80909
Contact: Site Public Contact    719-365-2406      
Principal Investigator: Kian Behbakht         
Kaiser Permanente-Franklin Recruiting
Denver, Colorado, United States, 80205
Contact: Site Public Contact    303-764-5056    josh.b.gordon@nsmtp.kp.org   
Principal Investigator: Alexander Menter         
Rocky Mountain Cancer Centers-Rose Suspended
Denver, Colorado, United States, 80220
Poudre Valley Hospital Recruiting
Fort Collins, Colorado, United States, 80524
Contact: Site Public Contact    970-297-6150      
Principal Investigator: Kian Behbakht         
Kaiser Permanente-Rock Creek Recruiting
Lafayette, Colorado, United States, 80026
Contact: Site Public Contact    303-764-5056    josh.b.gordon@nsmtp.kp.org   
Principal Investigator: Alexander Menter         
Kaiser Permanente-Lone Tree Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Site Public Contact    303-764-5056    josh.b.gordon@nsmtp.kp.org   
Principal Investigator: Alexander Menter         
United States, Connecticut
Danbury Hospital Recruiting
Danbury, Connecticut, United States, 06810
Contact: Site Public Contact    203-739-8074      
Principal Investigator: Linus T. Chuang         
Smilow Cancer Hospital Care Center-Fairfield Active, not recruiting
Fairfield, Connecticut, United States, 06824
Hartford Hospital Recruiting
Hartford, Connecticut, United States, 06102
Contact: Site Public Contact    860-545-5363      
Principal Investigator: Amy K. Brown         
Smilow Cancer Hospital Care Center at Saint Francis Active, not recruiting
Hartford, Connecticut, United States, 06105
Middlesex Hospital Suspended
Middletown, Connecticut, United States, 06457
The Hospital of Central Connecticut Recruiting
New Britain, Connecticut, United States, 06050
Contact: Site Public Contact    860-224-5660      
Principal Investigator: Amy K. Brown         
Yale University Active, not recruiting
New Haven, Connecticut, United States, 06520
Norwalk Hospital Recruiting
Norwalk, Connecticut, United States, 06856
Contact: Site Public Contact    203-852-2996    jennifer.long@norwalkhealth.org   
Principal Investigator: Linus T. Chuang         
Smilow Cancer Hospital Care Center-Trumbull Active, not recruiting
Trumbull, Connecticut, United States, 06611
United States, Delaware
Helen F Graham Cancer Center Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
Medical Oncology Hematology Consultants PA Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
Christiana Care Health System-Christiana Hospital Suspended
Newark, Delaware, United States, 19718
United States, District of Columbia
Sibley Memorial Hospital Recruiting
Washington, District of Columbia, United States, 20016
Contact: Site Public Contact    202-243-2373    jquiver1@jhmi.edu   
Principal Investigator: Deborah K. Armstrong         
United States, Florida
University of Florida Health Science Center - Gainesville Active, not recruiting
Gainesville, Florida, United States, 32610
Mount Sinai Medical Center Recruiting
Miami Beach, Florida, United States, 33140
Contact: Site Public Contact    305-674-2625    yenrique@msmc.com   
Principal Investigator: Michael A. Schwartz         
UF Cancer Center at Orlando Health Active, not recruiting
Orlando, Florida, United States, 32806
Sarasota Memorial Hospital Recruiting
Sarasota, Florida, United States, 34239
Contact: Site Public Contact    941-917-2225      
Principal Investigator: James V. Fiorica         
United States, Georgia
Emory University Hospital Midtown Recruiting
Atlanta, Georgia, United States, 30308
Contact: Site Public Contact    888-946-7447      
Principal Investigator: Namita Khanna         
Piedmont Hospital Recruiting
Atlanta, Georgia, United States, 30309
Contact: Site Public Contact    404-425-7943    ORS@piedmont.org   
Principal Investigator: Adam W. Nowlan         
Emory University Hospital/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Site Public Contact    404-778-1868      
Principal Investigator: Namita Khanna         
Northside Hospital Recruiting
Atlanta, Georgia, United States, 30342
Contact: Site Public Contact    404-303-3355    ClinicalTrials@northside.com   
Principal Investigator: Guilherme Henrique C. Cantuaria         
Augusta University Medical Center Recruiting
Augusta, Georgia, United States, 30912
Contact: Site Public Contact    706-721-2388    ga_cares@augusta.edu   
Principal Investigator: Sharad A. Ghamande         
WellStar Cobb Hospital Recruiting
Austell, Georgia, United States, 30106
Contact: Site Public Contact    470-793-4071    research@wellstar.org   
Principal Investigator: Jeffrey F. Hines         
WellStar Health System Inc Recruiting
Marietta, Georgia, United States, 30060
Contact: Site Public Contact    470-793-4071    research@wellstar.org   
Principal Investigator: Jeffrey F. Hines         
Wellstar Kennestone Hospital Recruiting
Marietta, Georgia, United States, 30060
Contact: Site Public Contact    470-793-4071    research@wellstar.org   
Principal Investigator: Jeffrey F. Hines         
WellStar North Fulton Hospital Recruiting
Roswell, Georgia, United States, 30076
Contact: Site Public Contact    470-793-4071    research@wellstar.org   
Principal Investigator: Jeffrey F. Hines         
Memorial Health University Medical Center Recruiting
Savannah, Georgia, United States, 31404
Contact: Site Public Contact    912-350-7887    clayter1@memorialhealth.com   
Principal Investigator: James J. Burke         
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Recruiting
Savannah, Georgia, United States, 31405
Contact: Site Public Contact    912-819-5704    underberga@sjchs.org   
Principal Investigator: Howard A. Zaren         
WellStar Vinings Health Park Recruiting
Smyrna, Georgia, United States, 30080
Contact: Site Public Contact    470-793-4071    research@wellstar.org   
Principal Investigator: Jeffrey F. Hines         
United States, Hawaii
Queen's Medical Center Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Site Public Contact    808-545-8548      
Principal Investigator: Michael E. Carney         
Kapiolani Medical Center for Women and Children Recruiting
Honolulu, Hawaii, United States, 96826
Contact: Site Public Contact    808-983-6090      
Principal Investigator: Michael E. Carney         
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute Suspended
Boise, Idaho, United States, 83712
Saint Luke's Mountain States Tumor Institute - Fruitland Suspended
Fruitland, Idaho, United States, 83619
Saint Luke's Mountain States Tumor Institute - Meridian Suspended
Meridian, Idaho, United States, 83642
Saint Luke's Mountain States Tumor Institute - Nampa Suspended
Nampa, Idaho, United States, 83686
United States, Illinois
Rush - Copley Medical Center Suspended
Aurora, Illinois, United States, 60504
Illinois CancerCare-Bloomington Suspended
Bloomington, Illinois, United States, 61704
Illinois CancerCare-Canton Suspended
Canton, Illinois, United States, 61520
Illinois CancerCare-Carthage Suspended
Carthage, Illinois, United States, 62321
Centralia Oncology Clinic Suspended
Centralia, Illinois, United States, 62801
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Site Public Contact    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Edward J. Tanner         
John H Stroger Jr Hospital of Cook County Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact    312-864-5204      
Principal Investigator: Thomas E. Lad         
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact    312-942-5498    clinical_trials@rush.edu   
Principal Investigator: Summer B. Dewdney         
Presence Saint Joseph Hospital-Chicago Recruiting
Chicago, Illinois, United States, 60657
Contact: Site Public Contact    773-665-3109      
Principal Investigator: Ira A. Oliff         
Cancer Care Specialists of Illinois - Decatur Recruiting
Decatur, Illinois, United States, 62526
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Decatur Memorial Hospital Suspended
Decatur, Illinois, United States, 62526
Crossroads Cancer Center Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Illinois CancerCare-Eureka Suspended
Eureka, Illinois, United States, 61530
NorthShore University HealthSystem-Evanston Hospital Recruiting
Evanston, Illinois, United States, 60201
Contact: Site Public Contact    847-570-2109      
Principal Investigator: Mary T. Jenkins Vogel         
Illinois CancerCare-Galesburg Suspended
Galesburg, Illinois, United States, 61401
Northwestern Medicine Cancer Center Delnor Suspended
Geneva, Illinois, United States, 60134
NorthShore University HealthSystem-Glenbrook Hospital Recruiting
Glenview, Illinois, United States, 60026
Contact: Site Public Contact    847-570-2109      
Principal Investigator: Mary T. Jenkins Vogel         
NorthShore University HealthSystem-Highland Park Hospital Suspended
Highland Park, Illinois, United States, 60035
Sudarshan K Sharma MD Limited-Gynecologic Oncology Recruiting
Hinsdale, Illinois, United States, 60521
Contact: Site Public Contact    630-856-6757      
Principal Investigator: Sudarshan K. Sharma         
Illinois CancerCare-Kewanee Clinic Suspended
Kewanee, Illinois, United States, 61443
Illinois CancerCare-Macomb Suspended
Macomb, Illinois, United States, 61455
Illinois CancerCare-Ottawa Clinic Suspended
Ottawa, Illinois, United States, 61350
Illinois CancerCare-Pekin Suspended
Pekin, Illinois, United States, 61554
Illinois CancerCare-Peoria Suspended
Peoria, Illinois, United States, 61615
Illinois CancerCare-Peru Suspended
Peru, Illinois, United States, 61354
Illinois CancerCare-Princeton Suspended
Princeton, Illinois, United States, 61356
Springfield Clinic Recruiting
Springfield, Illinois, United States, 62702
Contact: Site Public Contact    800-444-7541      
Principal Investigator: Bryan A. Faller         
Memorial Medical Center Suspended
Springfield, Illinois, United States, 62781
Cancer Care Specialists of Illinois-Swansea Recruiting
Swansea, Illinois, United States, 62226
Contact: Site Public Contact    217-876-4740    rhamrick@dmhhs.org   
Principal Investigator: Bryan A. Faller         
Northwestern Medicine Cancer Center Warrenville Recruiting
Warrenville, Illinois, United States, 60555
Contact: Site Public Contact    630-315-1918    Claudine.Gamster@CadenceHealth.org   
Principal Investigator: Barbara M. Buttin         
Midwestern Regional Medical Center Recruiting
Zion, Illinois, United States, 60099
Contact: Site Public Contact    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Julian C. Schink         
United States, Indiana
Parkview Regional Medical Center Recruiting
Fort Wayne, Indiana, United States, 46845
Contact: Site Public Contact    877-784-4673      
Principal Investigator: Iwona Podzielinski         
Indiana University/Melvin and Bren Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Site Public Contact    317-278-5632    iutrials@iu.edu   
Principal Investigator: Jeanne M. Schilder         
Saint Vincent Hospital and Health Care Center Recruiting
Indianapolis, Indiana, United States, 46260
Contact: Site Public Contact    317-338-2194    research@stvincent.org   
Principal Investigator: Michael J. Callahan         
Reid Health Recruiting
Richmond, Indiana, United States, 47374
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Memorial Hospital of South Bend Recruiting
South Bend, Indiana, United States, 46601
Contact: Site Public Contact    800-284-7370      
Principal Investigator: Nonyem A. Onujiogu         
United States, Iowa
Medical Oncology and Hematology Associates-West Des Moines Recruiting
Clive, Iowa, United States, 50325
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Mercy Cancer Center-West Lakes Recruiting
Clive, Iowa, United States, 50325
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Iowa Methodist Medical Center Recruiting
Des Moines, Iowa, United States, 50309
Contact: Site Public Contact    515-241-6727      
Principal Investigator: Robert J. Behrens         
Medical Oncology and Hematology Associates-Des Moines Suspended
Des Moines, Iowa, United States, 50309
Medical Oncology and Hematology Associates-Laurel Recruiting
Des Moines, Iowa, United States, 50314
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
Mercy Medical Center - Des Moines Recruiting
Des Moines, Iowa, United States, 50314
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
University of Iowa/Holden Comprehensive Cancer Center Recruiting
Iowa City, Iowa, United States, 52242
Contact: Site Public Contact    800-237-1225      
Principal Investigator: David P. Bender         
Siouxland Regional Cancer Center Recruiting
Sioux City, Iowa, United States, 51101
Contact: Site Public Contact    712-252-9326    HoopingarnerT@jencc.com   
Principal Investigator: Donald B. Wender         
Mercy Medical Center-West Lakes Recruiting
West Des Moines, Iowa, United States, 50266
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
United States, Kansas
Associates In Womens Health Suspended
Wichita, Kansas, United States, 67208
Ascension Via Christi Hospitals Wichita Recruiting
Wichita, Kansas, United States, 67214
Contact: Site Public Contact    800-362-0070    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
United States, Kentucky
Saint Elizabeth Medical Center South Recruiting
Edgewood, Kentucky, United States, 41017
Contact: Site Public Contact    859-301-5473    darla.hehman@stelizabeth.com   
Principal Investigator: Kevin M. Schuler         
University of Kentucky/Markey Cancer Center Recruiting
Lexington, Kentucky, United States, 40536
Contact: Site Public Contact    859-257-3379      
Principal Investigator: Frederick R. Ueland         
United States, Louisiana
Hematology/Oncology Clinic LLP Suspended
Baton Rouge, Louisiana, United States, 70809
Mary Bird Perkins Cancer Center Suspended
Baton Rouge, Louisiana, United States, 70809
Woman's Hospital Recruiting
Baton Rouge, Louisiana, United States, 70817
Contact: Site Public Contact    225-215-1353    Clinicalreserach@marybird.com   
Principal Investigator: David S. Hanson         
Women's Cancer Care-Covington Recruiting
Covington, Louisiana, United States, 70433
Contact: Site Public Contact    225-215-1353    clinicalresearch@marybird.com   
Principal Investigator: Patricia S. Braly         
Ochsner Medical Center Jefferson Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Site Public Contact    504-703-8712    Gregory.Johnstone@ochsner.org   
Principal Investigator: Katrina S. Wade         
United States, Maine
Eastern Maine Medical Center Recruiting
Bangor, Maine, United States, 04401
Contact: Site Public Contact    207-973-4274      
Principal Investigator: Sarah J. Sinclair         
Lafayette Family Cancer Center-EMMC Recruiting
Brewer, Maine, United States, 04412
Contact: Site Public Contact    800-987-3005      
Principal Investigator: Sarah J. Sinclair         
Maine Medical Center- Scarborough Campus Recruiting
Scarborough, Maine, United States, 04074
Contact: Site Public Contact    207-396-8090    wrighd@mmc.org   
Principal Investigator: Christopher J. Darus         
United States, Maryland
Greater Baltimore Medical Center Recruiting
Baltimore, Maryland, United States, 21204
Contact: Site Public Contact    443-849-3706      
Principal Investigator: Paul Celano         
MedStar Franklin Square Medical Center/Weinberg Cancer Institute Recruiting
Baltimore, Maryland, United States, 21237
Contact: Site Public Contact    443-777-7364      
Principal Investigator: Pallavi P. Kumar         
Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting
Baltimore, Maryland, United States, 21287
Contact: Site Public Contact    410-955-8804    jhcccro@jhmi.edu   
Principal Investigator: Deborah K. Armstrong         
UM Upper Chesapeake Medical Center Active, not recruiting
Bel Air, Maryland, United States, 21014
National Institutes of Health Clinical Center Suspended
Bethesda, Maryland, United States, 20892
Richard A Henson Cancer Institute at Ocean Pines Recruiting
Ocean Pines, Maryland, United States, 21811
Contact: Site Public Contact    410-543-7017    stephanie.cason@peninsula.org   
Principal Investigator: Justinian R. Ngaiza         
Peninsula Regional Medical Center Recruiting
Salisbury, Maryland, United States, 21801
Contact: Site Public Contact    866-922-6237      
Principal Investigator: Justinian R. Ngaiza         
United States, Massachusetts
Brigham and Women's Hospital Suspended
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Site Public Contact    877-442-3324      
Principal Investigator: Joyce F. Liu         
UMass Memorial Medical Center - Memorial Division Recruiting
Worcester, Massachusetts, United States, 01605
Contact: Site Public Contact    508-856-6265      
Principal Investigator: Susan L. Zweizig         
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: J. R. Liu         
University of Michigan Comprehensive Cancer Center Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Site Public Contact    800-865-1125      
Principal Investigator: Jean Hansen         
Henry Ford Cancer Institute-Downriver Suspended
Brownstown, Michigan, United States, 48183
Henry Ford Macomb Hospital-Clinton Township Suspended
Clinton Township, Michigan, United States, 48038
Wayne State University/Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Robert T. Morris         
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Eleanor M. Walker         
Green Bay Oncology - Escanaba Recruiting
Escanaba, Michigan, United States, 49829
Contact: Site Public Contact    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Matthew L. Ryan         
Weisberg Cancer Treatment Center Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: Site Public Contact    313-576-9790    ctoadmin@karmanos.org   
Principal Investigator: Robert T. Morris         
Spectrum Health at Butterworth Campus Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Sparrow Hospital Recruiting
Lansing, Michigan, United States, 48912
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: J. R. Liu         
Saint Joseph Mercy Oakland Suspended
Pontiac, Michigan, United States, 48341
Munson Medical Center Recruiting
Traverse City, Michigan, United States, 49684
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Henry Ford West Bloomfield Hospital Suspended
West Bloomfield, Michigan, United States, 48322
United States, Minnesota
Sanford Joe Lueken Cancer Center Recruiting
Bemidji, Minnesota, United States, 56601
Contact: Site Public Contact    218-333-5000    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Maria C. Bell         
Fairview Ridges Hospital Recruiting
Burnsville, Minnesota, United States, 55337
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Rachel E. Lerner         
Mercy Hospital Recruiting
Coon Rapids, Minnesota, United States, 55433
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Rachel E. Lerner         
Fairview-Southdale Hospital Recruiting
Edina, Minnesota, United States, 55435
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Rachel E. Lerner         
Mayo Clinic Health Systems-Mankato Active, not recruiting
Mankato, Minnesota, United States, 56001
Fairview Maple Grove Medical Center Recruiting
Maple Grove, Minnesota, United States, 55369
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Rachel E. Lerner         
Saint John's Hospital - Healtheast Recruiting
Maplewood, Minnesota, United States, 55109
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Rachel E. Lerner         
Abbott-Northwestern Hospital Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Rachel E. Lerner         
University of Minnesota/Masonic Cancer Center Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Site Public Contact    612-624-2620      
Principal Investigator: Melissa A. Geller         
Mayo Clinic Active, not recruiting
Rochester, Minnesota, United States, 55905
Park Nicollet Clinic - Saint Louis Park Recruiting
Saint Louis Park, Minnesota, United States, 55416
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Rachel E. Lerner         
Regions Hospital Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Rachel E. Lerner         
United Hospital Recruiting
Saint Paul, Minnesota, United States, 55102
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Rachel E. Lerner         
Saint Francis Regional Medical Center Suspended
Shakopee, Minnesota, United States, 55379
Minnesota Oncology Hematology PA-Woodbury Recruiting
Woodbury, Minnesota, United States, 55125
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Rachel E. Lerner         
United States, Mississippi
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 39216
Contact: Site Public Contact    601-815-6700      
Principal Investigator: Kelly J. Wilkinson         
United States, Missouri
Saint Francis Medical Center Suspended
Cape Girardeau, Missouri, United States, 63703
University of Missouri - Ellis Fischel Recruiting
Columbia, Missouri, United States, 65212
Contact: Site Public Contact    573-882-7440      
Principal Investigator: Erin R. Tuller         
Mercy Hospital Joplin Suspended
Joplin, Missouri, United States, 64804
Barnes-Jewish Hospital Suspended
Saint Louis, Missouri, United States, 63110
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Site Public Contact    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: David G. Mutch         
Mercy Hospital Springfield Recruiting
Springfield, Missouri, United States, 65804
Contact: Site Public Contact    417-269-4520      
Principal Investigator: Jay W. Carlson         
CoxHealth South Hospital Suspended
Springfield, Missouri, United States, 65807
United States, Montana
Billings Clinic Cancer Center Recruiting
Billings, Montana, United States, 59101
Contact: Site Public Contact    800-996-2663    research@billingsclinic.org   
Principal Investigator: John M. Schallenkamp         
Benefis Healthcare- Sletten Cancer Institute Suspended
Great Falls, Montana, United States, 59405
United States, Nebraska
CHI Health Saint Francis Recruiting
Grand Island, Nebraska, United States, 68803
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
CHI Health Good Samaritan Suspended
Kearney, Nebraska, United States, 68847
Nebraska Methodist Hospital Recruiting
Omaha, Nebraska, United States, 68114
Contact: Site Public Contact    402-354-5144      
Principal Investigator: Brent J. Tierney         
Alegent Health Bergan Mercy Medical Center Suspended
Omaha, Nebraska, United States, 68124
Alegent Health Lakeside Hospital Suspended
Omaha, Nebraska, United States, 68130
United States, Nevada
Women's Cancer Center of Nevada Recruiting
Las Vegas, Nevada, United States, 89169
Contact: Site Public Contact    702-693-6870    kmcwhirter@wccenter.com   
Principal Investigator: Nicola M. Spirtos         
United States, New Hampshire
Dartmouth Hitchcock Medical Center Suspended
Lebanon, New Hampshire, United States, 03756
Norris Cotton Cancer Center-Nashua Suspended
Nashua, New Hampshire, United States, 03063
United States, New Jersey
Cooper Hospital University Medical Center Recruiting
Camden, New Jersey, United States, 08103
Contact: Site Public Contact    856-325-6757      
Principal Investigator: David P. Warshal         
Morristown Medical Center Recruiting
Morristown, New Jersey, United States, 07960
Contact: Site Public Contact    973-971-5900      
Principal Investigator: Allison R. Wagreich         
Jersey Shore Medical Center Recruiting
Neptune, New Jersey, United States, 07753
Contact: Site Public Contact    732-776-4240      
Principal Investigator: Karim S. ElSahwi         
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Site Public Contact    732-235-8675      
Principal Investigator: Mihae Song         
Robert Wood Johnson University Hospital Somerset Recruiting
Somerville, New Jersey, United States, 08876
Contact: Site Public Contact    908-685-2481      
Principal Investigator: Mihae Song         
Overlook Hospital Recruiting
Summit, New Jersey, United States, 07902
Contact: Site Public Contact    908-522-2043      
Principal Investigator: Allison R. Wagreich         
MD Anderson Cancer Center at Cooper-Voorhees Suspended
Voorhees, New Jersey, United States, 08043
United States, New Mexico
University of New Mexico Cancer Center Recruiting
Albuquerque, New Mexico, United States, 87102
Contact: Site Public Contact    505-925-0366    LByatt@nmcca.org   
Principal Investigator: Carolyn Y. Muller         
Southwest Gynecologic Oncology Associates Inc Recruiting
Albuquerque, New Mexico, United States, 87106
Contact: Site Public Contact    505-272-0530    RDraper@nmcca.org   
Principal Investigator: Carolyn Y. Muller         
Memorial Medical Center - Las Cruces Recruiting
Las Cruces, New Mexico, United States, 88011
Contact: Site Public Contact    575-556-6545    Kim.Hoffman@lpnt.net   
Principal Investigator: Carolyn Y. Muller         
United States, New York
Women's Cancer Care Associates LLC Recruiting
Albany, New York, United States, 12208
Contact: Site Public Contact    518-458-1390    jbarlin@womenscancercareassociates.com   
Principal Investigator: Joyce N. Barlin         
Montefiore Medical Center-Einstein Campus Recruiting
Bronx, New York, United States, 10461
Contact: Site Public Contact    718-379-6866    aaraiza@montefiore.org   
Principal Investigator: Nicole S. Nevadunsky         
State University of New York Downstate Medical Center Active, not recruiting
Brooklyn, New York, United States, 11203
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Site Public Contact    800-767-9355    askroswell@roswellpark.org   
Principal Investigator: Shashikant B. Lele         
Laura and Isaac Perlmutter Cancer Center at NYU Langone Recruiting
New York, New York, United States, 10016
Contact: Site Public Contact    212-263-4434    prmc.coordinator@nyumc.org   
Principal Investigator: Bhavana Pothuri         
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Site Public Contact    585-275-5830      
Principal Investigator: Richard G. Moore         
Stony Brook University Medical Center Active, not recruiting
Stony Brook, New York, United States, 11794
State University of New York Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Contact: Site Public Contact    315-464-5476      
Principal Investigator: Mary J. Cunningham         
Dickstein Cancer Treatment Center Recruiting
White Plains, New York, United States, 10601
Contact: Site Public Contact    914-849-7582    mcortese@wphospital.org   
Principal Investigator: Dan Costin         
United States, North Carolina
UNC Lineberger Comprehensive Cancer Center Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Site Public Contact    877-668-0683    cancerclinicaltrials@med.unc.edu   
Principal Investigator: Linda Van Le         
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Site Public Contact    888-275-3853      
Principal Investigator: Angeles A. Secord         
Southeastern Medical Oncology Center-Goldsboro Suspended
Goldsboro, North Carolina, United States, 27534
Margaret R Pardee Memorial Hospital Recruiting
Hendersonville, North Carolina, United States, 28791
Contact: Site Public Contact    828-696-4716    karen.morris@unchealth.unc.edu   
Principal Investigator: James E. Radford         
Southeastern Medical Oncology Center-Jacksonville Suspended
Jacksonville, North Carolina, United States, 28546
FirstHealth of the Carolinas-Moore Regional Hospital Recruiting
Pinehurst, North Carolina, United States, 28374
Contact: Site Public Contact    910-715-3500    jcwilliams@firsthealth.org   
Principal Investigator: Michael J. Sundborg         
Duke Raleigh Hospital Suspended
Raleigh, North Carolina, United States, 27609
New Hanover Regional Medical Center/Zimmer Cancer Center Suspended
Wilmington, North Carolina, United States, 28401
Wake Forest University Health Sciences Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Site Public Contact    336-713-6771      
Principal Investigator: Samuel S. Lentz         
United States, North Dakota
Sanford Bismarck Medical Center Recruiting
Bismarck, North Dakota, United States, 58501
Contact: Site Public Contact    701-323-5760    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Maria C. Bell         
Sanford Broadway Medical Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Site Public Contact    701-323-5760    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Maria C. Bell         
Sanford Roger Maris Cancer Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Site Public Contact    701-234-6161    OncologyClinicalTrialsFargo@sanfordhealth.org   
Principal Investigator: Maria C. Bell         
United States, Ohio
Cleveland Clinic Akron General Recruiting
Akron, Ohio, United States, 44307
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Esther H. Rehmus         
Miami Valley Hospital South Recruiting
Centerville, Ohio, United States, 45459
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
University of Cincinnati/Barrett Cancer Center Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Site Public Contact    513-558-4553    uchealthnews@uc.edu   
Principal Investigator: Thomas J. Herzog         
Good Samaritan Hospital - Cincinnati Recruiting
Cincinnati, Ohio, United States, 45220
Contact: Site Public Contact    308-398-6518    clinicaltrials@sfmc-gi.org   
Principal Investigator: Richard L. Deming         
TriHealth Cancer Institute-Westside Suspended
Cincinnati, Ohio, United States, 45247
MetroHealth Medical Center Recruiting
Cleveland, Ohio, United States, 44109
Contact: Site Public Contact    216-778-8526    dstrater@metrohealth.org   
Principal Investigator: Kimberly E. Resnick         
Cleveland Clinic Cancer Center/Fairview Hospital Recruiting
Cleveland, Ohio, United States, 44111
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Peter G. Rose         
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Peter G. Rose         
Ohio State University Comprehensive Cancer Center Suspended
Columbus, Ohio, United States, 43210
Riverside Methodist Hospital Recruiting
Columbus, Ohio, United States, 43214
Contact: Site Public Contact    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Grandview Hospital Suspended
Dayton, Ohio, United States, 45405
Orion Cancer Care Recruiting
Findlay, Ohio, United States, 45840
Contact: Site Public Contact    937-775-1350    som_dcop@wright.edu   
Principal Investigator: Howard M. Gross         
Hillcrest Hospital Cancer Center Recruiting
Mayfield Heights, Ohio, United States, 44124
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Peter G. Rose         
ProMedica Flower Hospital Recruiting
Sylvania, Ohio, United States, 43560
Contact: Site Public Contact    419-824-1842      
Principal Investigator: Adam C. Walter         
The Toledo Hospital/Toledo Children's Hospital Suspended
Toledo, Ohio, United States, 43606
Wright-Patterson Medical Center Active, not recruiting
Wright-Patterson Air Force Base, Ohio, United States, 45433-5529
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Katherine M. Moxley         
Oklahoma Cancer Specialists and Research Institute-Tulsa Recruiting
Tulsa, Oklahoma, United States, 74146
Contact: Site Public Contact    918-505-3200      
Principal Investigator: Katherine M. Moxley         
United States, Oregon
Saint Charles Health System Recruiting
Bend, Oregon, United States, 97701
Contact: Site Public Contact    541-706-2909    nosall@stcharleshealthcare.org   
Principal Investigator: Dan S. Zuckerman         
Legacy Mount Hood Medical Center Active, not recruiting
Gresham, Oregon, United States, 97030
Legacy Good Samaritan Hospital and Medical Center Recruiting
Portland, Oregon, United States, 97210
Contact: Site Public Contact    800-220-4937    cancer@lhs.org   
Principal Investigator: Colleen C. McCormick         
Legacy Meridian Park Hospital Recruiting
Tualatin, Oregon, United States, 97062
Contact: Site Public Contact    503-413-1742      
Principal Investigator: Colleen C. McCormick         
United States, Pennsylvania
Abington Memorial Hospital Suspended
Abington, Pennsylvania, United States, 19001
Saint Luke's University Hospital-Bethlehem Campus Recruiting
Bethlehem, Pennsylvania, United States, 18015
Contact: Site Public Contact    484-503-4151      
Principal Investigator: Nicholas P. Taylor         
Bryn Mawr Hospital Suspended
Bryn Mawr, Pennsylvania, United States, 19010
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822
Contact: Site Public Contact    570-271-5251    HemonCCTrials@geisinger.edu   
Principal Investigator: Rajiv Panikkar         
Ephrata Cancer Center Recruiting
Ephrata, Pennsylvania, United States, 17522
Contact: Site Public Contact    717-721-4840      
Principal Investigator: Mark A. Miller         
Ephrata Community Hospital Suspended
Ephrata, Pennsylvania, United States, 17522
Adams Cancer Center Suspended
Gettysburg, Pennsylvania, United States, 17325
Cherry Tree Cancer Center Suspended
Hanover, Pennsylvania, United States, 17331
UPMC Pinnacle Cancer Center/Community Osteopathic Campus Active, not recruiting
Harrisburg, Pennsylvania, United States, 17109
Sechler Family Cancer Center Recruiting
Lebanon, Pennsylvania, United States, 17042
Contact: Site Public Contact    717-741-8303    doxenberg@wellspan.org   
Principal Investigator: Mark A. Miller         
Geisinger Medical Oncology-Lewisburg Recruiting
Lewisburg, Pennsylvania, United States, 17837
Contact: Site Public Contact    570-374-8555    HemonCCTrials@geisinger.edu   
Principal Investigator: Rajiv Panikkar         
Paoli Memorial Hospital Recruiting
Paoli, Pennsylvania, United States, 19301
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
University of Pennsylvania/Abramson Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Site Public Contact    800-474-9892      
Principal Investigator: Ashley F. Haggerty         
West Penn Hospital Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Site Public Contact    412-578-5000      
Principal Investigator: Sarah M. Crafton         
Guthrie Medical Group PC-Robert Packer Hospital Recruiting
Sayre, Pennsylvania, United States, 18840
Contact: Site Public Contact    800-836-0388      
Principal Investigator: Philip A. Lowry         
Reading Hospital Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Site Public Contact    610-988-9323      
Principal Investigator: Terrence P. Cescon         
UPMC Susquehanna Suspended
Williamsport, Pennsylvania, United States, 17701
Abington Memorial Hospital-Asplundh Cancer Pavilion Recruiting
Willow Grove, Pennsylvania, United States, 19090
Contact: Site Public Contact    215-481-2402      
Principal Investigator: Mark S. Shahin         
Lankenau Medical Center Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Site Public Contact    484-476-2649    turzoe@mlhs.org   
Principal Investigator: Albert S. DeNittis         
WellSpan Health-York Hospital Recruiting
York, Pennsylvania, United States, 17403
Contact: Site Public Contact    877-441-7957      
Principal Investigator: Mark A. Miller         
United States, Rhode Island
Women and Infants Hospital Recruiting
Providence, Rhode Island, United States, 02905
Contact: Site Public Contact    401-274-1122      
Principal Investigator: Paul A. DiSilvestro         
United States, South Carolina
AnMed Health Cancer Center Recruiting
Anderson, South Carolina, United States, 29621
Contact: Site Public Contact    864-512-4651    rhonda.ballew@anmedhealth.org   
Principal Investigator: David Griffin         
Gibbs Cancer Center-Gaffney Active, not recruiting
Gaffney, South Carolina, United States, 29341
Saint Francis Hospital Recruiting
Greenville, South Carolina, United States, 29601
Contact: Site Public Contact    864-603-6213    meissa_beckman@bshsi.org   
Principal Investigator: David Griffin         
Saint Francis Cancer Center Recruiting
Greenville, South Carolina, United States, 29607
Contact: Site Public Contact    864-603-6213    meissa_beckman@bshsi.org   
Principal Investigator: David Griffin         
Gibbs Cancer Center-Pelham Active, not recruiting
Greer, South Carolina, United States, 29651
South Carolina Cancer Specialists PC Recruiting
Hilton Head Island, South Carolina, United States, 29926-3827
Contact: Site Public Contact    912-819-5704    underberga@sjchs.org   
Principal Investigator: Howard A. Zaren         
Spartanburg Medical Center Active, not recruiting
Spartanburg, South Carolina, United States, 29303
MGC Hematology Oncology-Union Active, not recruiting
Union, South Carolina, United States, 29379
United States, South Dakota
Rapid City Regional Hospital Recruiting
Rapid City, South Dakota, United States, 57701
Contact: Site Public Contact    605-716-3982    research@rcrh.org   
Principal Investigator: Helen L. Frederickson         
Sanford Cancer Center Oncology Clinic Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Site Public Contact    605-312-3320    OncologyClinicTrialsSF@sanfordhealth.org   
Principal Investigator: Maria C. Bell         
Avera Cancer Institute Suspended
Sioux Falls, South Dakota, United States, 57105
Sanford USD Medical Center - Sioux Falls Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Site Public Contact    605-312-3320    OncologyClinicalTrialsSF@SanfordHealth.org   
Principal Investigator: Maria C. Bell         
United States, Tennessee
Regional Cancer Center at Indian Path Community Hospital Recruiting
Kingsport, Tennessee, United States, 37660
Contact: Site Public Contact    423-578-8538    Justin.reynolds@balladhealth.org   
Principal Investigator: Asheesh Shipstone         
Wellmont Holston Valley Hospital and Medical Center Recruiting
Kingsport, Tennessee, United States, 37660
Contact: Site Public Contact    423-578-8538    justin.reynolds@wellmont.org   
Principal Investigator: Asheesh Shipstone         
Thompson Cancer Survival Center Recruiting
Knoxville, Tennessee, United States, 37916
Contact: Site Public Contact    865-331-1812      
Principal Investigator: Brook A. Saunders         
Thompson Cancer Survival Center - West Recruiting
Knoxville, Tennessee, United States, 37932
Contact: Site Public Contact    865-331-1812      
Principal Investigator: Brook A. Saunders         
Vanderbilt University/Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Site Public Contact    800-811-8480      
Principal Investigator: Alaina J. Brown         
United States, Texas
Parkland Memorial Hospital Recruiting
Dallas, Texas, United States, 75235
Contact: Site Public Contact    214-590-5582    canceranswerline@UTSouthwestern.edu   
Principal Investigator: Jayanthi S. Lea         
UT Southwestern/Simmons Cancer Center-Dallas Recruiting
Dallas, Texas, United States, 75390
Contact: Site Public Contact    214-648-7097    canceranswerline@UTSouthwestern.edu   
Principal Investigator: Jayanthi S. Lea         
The Methodist Hospital System Active, not recruiting
Houston, Texas, United States, 77030
Methodist Willowbrook Hospital Active, not recruiting
Houston, Texas, United States, 77070
Houston Methodist Sugar Land Hospital Active, not recruiting
Sugar Land, Texas, United States, 77479
United States, Utah
Intermountain Medical Center Recruiting
Murray, Utah, United States, 84107
Contact: Site Public Contact    801-507-3950    officeofresearch@imail.org   
Principal Investigator: Derrick S. Haslem         
Dixie Medical Center Regional Cancer Center Recruiting
Saint George, Utah, United States, 84770
Contact: Site Public Contact    435-688-4167    officeofresearch@imail.org   
Principal Investigator: Derrick S. Haslem         
Utah Cancer Specialists-Salt Lake City Recruiting
Salt Lake City, Utah, United States, 84106
Contact: Site Public Contact    801-933-6070    officeofresearch@imail.org   
Principal Investigator: Derrick S. Haslem         
Huntsman Cancer Institute/University of Utah Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Site Public Contact    888-424-2100    cancerinfo@hci.utah.edu   
Principal Investigator: Theresa L. Werner         
South Jordan Health Center Suspended
South Jordan, Utah, United States, 84009
United States, Vermont
Central Vermont Medical Center/National Life Cancer Treatment Suspended
Berlin, Vermont, United States, 05602
University of Vermont Medical Center Recruiting
Burlington, Vermont, United States, 05401
Contact: Site Public Contact    802-656-4101    rpo@uvm.edu   
Principal Investigator: Evelyn Cantillo         
University of Vermont and State Agricultural College Suspended
Burlington, Vermont, United States, 05405
United States, Virginia
University of Virginia Cancer Center Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Site Public Contact    434-243-6303    PAS9E@virginia.edu   
Principal Investigator: Linda R. Duska         
Virginia Commonwealth University/Massey Cancer Center Recruiting
Richmond, Virginia, United States, 23298
Contact: Site Public Contact    804-628-1914    klcampbell@vcu.edu   
Principal Investigator: Sarah W. Gordon         
United States, Washington
PeaceHealth Saint Joseph Medical Center Recruiting
Bellingham, Washington, United States, 98225
Contact: Site Public Contact    360-715-4133    mjohnson9@peacehealth.org   
Principal Investigator: Dan S. Zuckerman         
Swedish Cancer Institute-Edmonds Recruiting
Edmonds, Washington, United States, 98026
Contact: Site Public Contact    206-215-3086    PCRC-NCORP@Swedish.org   
Principal Investigator: Dan S. Zuckerman         
Kadlec Clinic Hematology and Oncology Suspended
Kennewick, Washington, United States, 99336
Skagit Valley Hospital Regional Cancer Care Center Active, not recruiting
Mount Vernon, Washington, United States, 98274
Skagit Valley Hospital Active, not recruiting
Mount Vernon, Washington, United States, 98274
Pacific Gynecology Specialists Suspended
Seattle, Washington, United States, 98104
Fred Hutchinson Cancer Research Center Suspended
Seattle, Washington, United States, 98109
Seattle Cancer Care Alliance Recruiting
Seattle, Washington, United States, 98109
Contact: Site Public Contact    800-804-8824      
Principal Investigator: Heidi J. Gray         
Swedish Medical Center-First Hill Recruiting
Seattle, Washington, United States, 98122-4307
Contact: Site Public Contact    206-215-3086    PCRC-NCORP@Swedish.org   
Principal Investigator: Dan S. Zuckerman         
Northwest Hospital Active, not recruiting
Seattle, Washington, United States, 98133
Women's Cancer Center of Seattle Active, not recruiting
Seattle, Washington, United States, 98133
University of Washington Medical Center Suspended
Seattle, Washington, United States, 98195
Legacy Salmon Creek Hospital Recruiting
Vancouver, Washington, United States, 98686
Contact: Site Public Contact    503-413-2150      
Principal Investigator: Colleen C. McCormick         
Wenatchee Valley Hospital and Clinics Active, not recruiting
Wenatchee, Washington, United States, 98801
United States, West Virginia
West Virginia University Charleston Division Recruiting
Charleston, West Virginia, United States, 25304
Contact: Site Public Contact    304-388-9944      
Principal Investigator: Steven J. Jubelirer         
Edwards Comprehensive Cancer Center Recruiting
Huntington, West Virginia, United States, 25701
Contact: Site Public Contact    304-399-6617      
Principal Investigator: Maria R. Tria Tirona         
Monongalia Hospital Recruiting
Morgantown, West Virginia, United States, 26505
Contact: Site Public Contact    304-598-6560      
Principal Investigator: William C. McBee         
United States, Wisconsin
Aurora Cancer Care-Southern Lakes VLCC Recruiting
Burlington, Wisconsin, United States, 53105
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Marshfield Clinic-Chippewa Center Suspended
Chippewa Falls, Wisconsin, United States, 54729
Marshfield Clinic Cancer Center at Sacred Heart Suspended
Eau Claire, Wisconsin, United States, 54701
Aurora Health Center-Fond du Lac Recruiting
Fond Du Lac, Wisconsin, United States, 54937
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Aurora Health Care Germantown Health Center Recruiting
Germantown, Wisconsin, United States, 53022
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Aurora Cancer Care-Grafton Recruiting
Grafton, Wisconsin, United States, 53024
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Saint Vincent Hospital Cancer Center Green Bay Recruiting
Green Bay, Wisconsin, United States, 54301
Contact: Site Public Contact    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Matthew L. Ryan         
Saint Vincent Hospital Cancer Center at Saint Mary's Recruiting
Green Bay, Wisconsin, United States, 54303
Contact: Site Public Contact    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Matthew L. Ryan         
Aurora BayCare Medical Center Recruiting
Green Bay, Wisconsin, United States, 54311
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Aurora Cancer Care-Kenosha South Recruiting
Kenosha, Wisconsin, United States, 53142
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Gundersen Lutheran Medical Center Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Site Public Contact    608-775-2385    cancerctr@gundersenhealth.org   
Principal Investigator: Kurt Oettel         
Marshfield Clinic - Ladysmith Center Suspended
Ladysmith, Wisconsin, United States, 54848
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: Site Public Contact    800-622-8922      
Principal Investigator: Lisa M. Barroilhet         
Aurora Bay Area Medical Group-Marinette Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Saint Vincent Hospital Cancer Center at Marinette Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Site Public Contact    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Matthew L. Ryan         
Marshfield Medical Center-Marshfield Suspended
Marshfield, Wisconsin, United States, 54449
Aurora Cancer Care-Milwaukee Recruiting
Milwaukee, Wisconsin, United States, 53209
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Aurora Saint Luke's Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53215
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Site Public Contact    414-805-3666      
Principal Investigator: William H. Bradley         
Aurora Sinai Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53233
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Marshfield Clinic-Minocqua Center Suspended
Minocqua, Wisconsin, United States, 54548
ProHealth D N Greenwald Center Suspended
Mukwonago, Wisconsin, United States, 53149
ProHealth Oconomowoc Memorial Hospital Suspended
Oconomowoc, Wisconsin, United States, 53066
Saint Vincent Hospital Cancer Center at Oconto Falls Recruiting
Oconto Falls, Wisconsin, United States, 54154
Contact: Site Public Contact    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Matthew L. Ryan         
Vince Lombardi Cancer Clinic - Oshkosh Recruiting
Oshkosh, Wisconsin, United States, 54904
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Aurora Cancer Care-Racine Recruiting
Racine, Wisconsin, United States, 53406
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Marshfield Medical Center-Rice Lake Suspended
Rice Lake, Wisconsin, United States, 54868
Vince Lombardi Cancer Clinic-Sheboygan Recruiting
Sheboygan, Wisconsin, United States, 53081
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Ascension Saint Michael's Hospital Suspended
Stevens Point, Wisconsin, United States, 54481
Marshfield Clinic Stevens Point Center Suspended
Stevens Point, Wisconsin, United States, 54482
Saint Vincent Hospital Cancer Center at Sturgeon Bay Recruiting
Sturgeon Bay, Wisconsin, United States, 54235-1495
Contact: Site Public Contact    920-433-8889    Christy.Gilchrist@hshs.org   
Principal Investigator: Matthew L. Ryan         
Aurora Medical Center in Summit Recruiting
Summit, Wisconsin, United States, 53066
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Vince Lombardi Cancer Clinic-Two Rivers Recruiting
Two Rivers, Wisconsin, United States, 54241
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
ProHealth Waukesha Memorial Hospital Suspended
Waukesha, Wisconsin, United States, 53188
UW Cancer Center at ProHealth Care Suspended
Waukesha, Wisconsin, United States, 53188
Marshfield Clinic-Wausau Center Suspended
Wausau, Wisconsin, United States, 54401
Aurora Cancer Care-Milwaukee West Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Aurora West Allis Medical Center Recruiting
West Allis, Wisconsin, United States, 53227
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Elizabeth L. Dickson Michelson         
Marshfield Clinic - Weston Center Suspended
Weston, Wisconsin, United States, 54476
Marshfield Clinic - Wisconsin Rapids Center Suspended
Wisconsin Rapids, Wisconsin, United States, 54494
Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Site Public Contact    780-432-8500      
Principal Investigator: Xiaofu Zhu         
Canada, Ontario
Royal Victoria Regional Health Centre Recruiting
Barrie, Ontario, Canada, L4M 6M2
Contact: Site Public Contact    705-739-5661      
Principal Investigator: Allison L. Ball         
Juravinski Cancer Centre at Hamilton Health Sciences Recruiting
Hamilton, Ontario, Canada, L8V 5C2
Contact: Site Public Contact    905-387-9495      
Principal Investigator: Holger W. Hirte         
London Regional Cancer Program Recruiting
London, Ontario, Canada, N6A 4L6
Contact: Site Public Contact    519-685-8600      
Principal Investigator: Stephen A. Welch         
Algoma District Cancer Program Sault Area Hospital Recruiting
Sault Ste Marie, Ontario, Canada, P6B 0A8
Contact: Site Public Contact    705-759-3434      
Principal Investigator: Ioannis A. Voutsadakis         
Odette Cancer Centre- Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Site Public Contact    416-480-5000      
Principal Investigator: Helen J. Mackay         
University Health Network-Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Site Public Contact    416-946-4501    clinical.trials@uhn.on.ca   
Principal Investigator: Stephanie Lheureux         
Canada, Quebec
CHUM - Hopital Notre-Dame Suspended
Montreal, Quebec, Canada, H2L 4M1
CHUM - Centre Hospitalier de l'Universite de Montreal Recruiting
Montreal, Quebec, Canada, H2X 3E4
Contact: Site Public Contact    514-890-8000 ext 12725    info.cr.chum@ssss.gouv.qc.ca   
Principal Investigator: Diane M. Provencher         
Jewish General Hospital Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Site Public Contact    514-340-8222 ext 8248      
Principal Investigator: Susie K. Lau         
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) Recruiting
Quebec City, Quebec, Canada, G1R 2J6
Contact: Site Public Contact       rechclinique@crchuq.ulaval.ca   
Principal Investigator: Vincent Castonguay         
Japan
Hokkaido University Hospital Recruiting
Sapporo, Hokkaido, Japan, 060-8648
Contact: Site Public Contact       hassi@med.hokudai.ac.jp   
Principal Investigator: Hidemichi Watari         
Saitama Medical University International Medical Center Recruiting
Saitama, Japan, 350-1298
Contact: Site Public Contact    81-49-276-2028      
Principal Investigator: Hiroyuki Yoshida         
Sponsors and Collaborators
National Cancer Institute (NCI)
NRG Oncology
Investigators
Layout table for investigator information
Principal Investigator: Jung-min Lee NRG Oncology

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02502266     History of Changes
Other Study ID Numbers: NCI-2015-00651
NCI-2015-00651 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
NRG-GY005
s16-01681
NRG-GY005 ( Other Identifier: NRG Oncology )
NRG-GY005 ( Other Identifier: CTEP )
U10CA180868 ( U.S. NIH Grant/Contract )
First Posted: July 20, 2015    Key Record Dates
Last Update Posted: November 21, 2019
Last Verified: October 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Adenocarcinoma
Carcinoma, Transitional Cell
Cystadenocarcinoma, Serous
Carcinoma, Endometrioid
Adenocarcinoma, Clear Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Ovarian Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Cystadenocarcinoma
Neoplasms, Cystic, Mucinous, and Serous
Endometrial Neoplasms
Uterine Neoplasms
Paclitaxel
Doxorubicin
Liposomal doxorubicin
Topotecan
Olaparib
Cediranib
Maleic acid
Antineoplastic Agents, Phytogenic